More than 17 million patients in the United States have obstructive sleep apnea,1 a condition associated with sequelae such as daytime somnolence, motor vehicle crashes, and cardiovascular disease.2 Continuous positive airway pressure devices are the first-line treatment for obstructive sleep apnea, although the effectiveness of such treatment is often limited by patient noncompliance.2 Second-line treatments (eg, oral appliances and palatal surgery) exist, but the available evidence offers limited support for such alternatives.2
Rathi VK, Kondamuri NS, Naunheim MR, Gadkaree SK, Metson RB, Scangas GA. Use and Cost of a Hypoglossal Nerve Stimulator Device for Obstructive Sleep Apnea Between 2015 and 2018. JAMA Otolaryngol Head Neck Surg. 2019;145(10):975–977. doi:https://doi.org/10.1001/jamaoto.2019.2366
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: